What's in PARKEDALE's pipeline?

PARKEDALE has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with PARKEDALE's portfolio?

Top competitors by shared drug class: .

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/parkedale.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

PARKEDALE — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PARKEDALE pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Chloromycetin	chloramphenicol succinate	marketed	Amphenicol-class Antibacterial		Infectious Disease	1950-01-01
Chlorocidin	CHLORAMPHENICOL	marketed	Amphenicol-class Antibacterial	Cytochrome P450 3A4	Neuroscience	1950-01-01

Therapeutic area mix

Infectious Disease · 1
Neuroscience · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for PARKEDALE:

Cite this brief

Drug Landscape (2026). PARKEDALE — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/parkedale. Accessed 2026-05-16.